Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
Sign Up to like & getrecommendations! Published in 2021 at "Calcified tissue international"
DOI: 10.1007/s00223-020-00785-1
Abstract: Discontinuation of denosumab treatment is associated with rapid bone loss that could be prevented in many patients by zoledronate (ZOL) infusion given 6 months after the last denosumab injection. The effects, however, of zoledronate administration… read more here.
Keywords: versus months; early zol; zol infusion; zol ... See more keywords